Table of Contents PART 01: Executive summary PART 02: Research Methodology PART 03: Introduction • Key market highlights • Key vendor offerings PART 04: Disease Overview • Viral disease PART 05: Market landscape • Market overview • Five forces analysis PART 06: Pipeline analysis PART 07: Market segmentation by therapies • Global hepatitis therapeutics market • Global HIV/AIDS therapeutics market • Global herpes therapeutics market • Global influenza therapeutics market PART 08: Market segmentation by MOA • Reverse transcriptase inhibitors • Protease inhibitors • Entry/Fusion inhibitors • Immune system modulators PART 09: Geographical segmentation • Antiviral drugs market in Americas • Antiviral drugs market in EMEA • Antiviral drugs market in APAC PART 10: Decision framework PART 11: Drivers and challenges • Market drivers • Impact of drivers on key customer segments • Market challenges • Forcefield analysis of impact of drivers and challenges PART 12: Market trends • Technological advancements • Combination therapy • Mergers and acquisitions • Growing partnerships PART 13: Competitive Landscape • Competitive scenario PART 14: Key vendor analysis • Bristol-Myers Squibb • F. Hoffmann-La Roche • Gilead Sciences • GlaxoSmithKline • Other prominent vendors PART 15: Appendix • List of abbreviations List of Exhibits Exhibit 01: Few major products offered by the key vendors Exhibit 02: HIV treatment regimen approved by FDA Exhibit 03: Hepatitis treatment regimen approved by FDA Exhibit 04: Herpes treatment regimen approved by FDA Exhibit 05: Global antiviral drugs market snapshot Exhibit 06: Key marketed products Exhibit 07: Global antiviral drugs market 2016-2021 ($ billions) Exhibit 08: Opportunity analysis of global antiviral drugs market Exhibit 09: Snapshot of pipeline molecules (2016) Exhibit 10: Pipeline analysis Exhibit 11: Global antiviral drugs market segmentation by therapies Exhibit 12: Acute hepatitis cases in US 2000-2014 Exhibit 13: Global hepatitis therapeutics market 2016-2021 ($ billions) Exhibit 14: Global HIV/AIDS therapeutics market 2016-2021 ($ billions) Exhibit 15: Number of women patients with HSV 2 in US 2000-2014 Exhibit 16: Global herpes therapeutic market 2016-2021 ($ billions) Exhibit 17: Global influenza therapeutics market 2016-2021 ($ billions) Exhibit 18: Global antiviral drugs market segmentation by MOA Exhibit 19: Market share of different segments based on MOA 2016 Exhibit 20: Global antiviral drugs market segmentation by geography 2016 and 2021 Exhibit 21: Global antiviral drugs market revenue by geography 2016-2021 ($ billions) Exhibit 22: Market scenario in Americas Exhibit 23: Antiviral drugs market in Americas 2016-2021 ($ billions) Exhibit 24: Market scenario in EMEA Exhibit 25: Antiviral drugs market in EMEA 2016-2021 ($ billions) Exhibit 26: Market scenario in APAC Exhibit 27: Antiviral drugs market in APAC 2016-2021 ($ billions) Exhibit 28: Seasonal influenza vaccine: Total doses distributed in millions Exhibit 29: Impact of drivers Exhibit 30: Impact of challenges Exhibit 31: Competitive structure analysis of global antiviral drugs market 2016 Exhibit 32: Competitive analysis of global antiviral drugs market Exhibit 33: Bristol-Myers Squibb: Geographical segmentation in terms of revenue in 2015 Exhibit 34: Bristol-Myers Squibb: Strength assessment Exhibit 35: Bristol-Myers Squibb: Strategy assessment Exhibit 36: Bristol-Myers Squibb: Opportunity assessment Exhibit 37: F. Hoffman-La Roche: Strength assessment Exhibit 38: F. Hoffman-La Roche: Strategy assessment Exhibit 39: F. Hoffman-La Roche: Opportunity assessment Exhibit 40: Gilead Sciences: Strength assessment Exhibit 41: Gilead Sciences: Strategy assessment Exhibit 42: Gilead Sciences: Opportunity assessment Exhibit 43: GlaxoSmithKline: Strength assessment Exhibit 44: GlaxoSmithKline: Strategy assessment Exhibit 45: GlaxoSmithKline: Opportunity assessment

Bristol-Myers Squibb, F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, AbbVie, Johnson & Johnson, Merck, and Novartis.